2nd Quarter - Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$178,134
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 22, 2011 $185,000 Replaced
2nd Quarter - Amendment (this page) Dec 16, 2011 $178,134 Replaced
2nd Quarter - Amendment Jan 23, 2015 $178,134 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Small Business SMB

S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

LobbyistCovered position, as disclosed
ANNE CASSITY —
JOHN M COSTER —
ADNAN JALIL —
DAVID SANDERS —

Contacted: Office of Personnel Management (OPM); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); Drug Enforcement Administration (DEA); Food & Drug Administration (FDA); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); SENATE; Agency for Healthcare Research & Quality (AHRQ); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES

Bills named: S. 312 (112th), H.R. 605 (112th)

Pharmacy PHA

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

LobbyistCovered position, as disclosed
ANNE CASSITY —
JOHN M COSTER —
ADNAN JALIL —
DAVID SANDERS —

Contacted: Government Accountability Office (GAO); Agency for Healthcare Research & Quality (AHRQ); Drug Enforcement Administration (DEA); SENATE; Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Defense, Dept of (DOD); Food & Drug Administration (FDA); Office of Personnel Management (OPM); Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2939 (112th), H.R. 1971 (112th), H.R. 891 (112th), H.R. 1316 (112th), H.R. 1839 (112th), H.R. 1946 (112th), H.R. 866 (112th), H.R. 1041 (112th), H.R. 1936 (112th), H.R. 979 (112th), S. 1560 (112th), H.R. 1540 (112th), S. 274 (112th), S. 507 (112th), H.R. 1409 (112th), S. 1699 (112th), S. 1253 (112th), S. 1058 (112th), S. 513 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.